A new study shows that high-dose vitamin C may help kill pancreatic cancer cells, but only when given intravenously. Oral vitamin C cannot reach the high blood levels needed for an anti-cancer effect. In laboratory tests, intravenous-level vitamin C significantly reduced the survival of multiple pancreatic cancer cell lines. Researchers also found that iron plays […]
Recent advances are changing how doctors treat pancreatic cancer and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). For pancreatic cancer, a newer treatment called NALIRIFOX was approved in early 2024 for patients with metastatic disease. This combination therapy has shown improved survival, helping patients live about 11.1 months on average compared to 9.2 months with the previous standard
New Therapies Improve Outcomes in Pancreatic Cancer and GEP-NETs Read More »
The U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011, a next-generation CAR T-cell therapy developed by Caribou Biosciences for patients with relapsed or refractory multiple myeloma. In an early clinical trial, CB-011 showed strong results. Among 12 previously untreated patients, 92% responded to the therapy. About 75% achieved
FDA Grants RMAT Status to Off-the-Shelf CAR T Therapy CB-011 for Multiple Myeloma Read More »
A new study has found a strong link between exposure to Agent Orange and the development of myelodysplastic syndromes (MDS), a group of bone marrow cancers affecting blood cell production. Researchers discovered that veterans exposed to Agent Orange are twice as likely to carry high-risk genetic abnormalities. Mutations in genes such as TET2, SRSF2, and
Cogent Biosciences has submitted a new drug application to the U.S. Food and Drug Administration for bezuclastinib to treat patients with gastrointestinal stromal tumors (GIST) who have already been treated with imatinib. The application is for bezuclastinib used together with sunitinib. In the Phase 3 PEAK trial, the combination showed clear benefits. Patients receiving both
The U.S. Food and Drug Administration has delayed its decision on Orca Bio’s cell therapy Orca-T, a treatment designed for blood cancers like AML, ALL, and MDS. The new target date for approval is now July 6, 2026, instead of April 6. The delay is due to the company submitting additional manufacturing and chemistry information
FDA Delays Decision on Orca-T Cell Therapy Despite Strong Clinical Results Read More »
A new study sheds light on why pancreatic cancer is so aggressive. Researchers found that pancreatic ductal adenocarcinoma (PDAC) reactivates genes normally only active during fetal development. This “onco-fetal” behavior may help explain the cancer’s rapid growth and resistance to treatment. The team examined stem cell markers in fetal, adult, and cancerous pancreatic tissues. They
Pancreatic Cancer Reactivates Fetal Genes to Drive Aggressive Growth Read More »
Researchers have found that unexpected findings on lung cancer CT scans can reveal other hidden cancers. By analyzing data from over 26,000 participants in the National Lung Screening Trial, the team identified non-lung abnormalities that may signal undiagnosed cancers and need prompt follow-up. The study showed that about 3% of scans revealed issues in organs
CT Scans for Lung Cancer Can Reveal Hidden Cancers Read More »
Researchers have discovered how CD8+ T cells use the amino acid cysteine to balance two competing tasks: multiplying and killing cancer cells. The study, published in Cell, found that cysteine is split inside T cells between two pathways. One pathway helps T cells grow by using cysteine to make iron-sulfur (FeS) clusters through the enzyme
Study Reveals How T Cells Can Be Supercharged to Fight Cancer Read More »
CellCentric has treated the first patient in the DOMMINO-1 trial, a Phase 2 study testing an all-oral combination of inobrodib, pomalidomide, and dexamethasone (InoPd) for patients with heavily pretreated, relapsed or refractory multiple myeloma. The trial plans to enroll 100 patients in the US and UK, focusing on those who are “triple-class refractory” and often